trial

Clinical Trial of Tolcapone for Cognition in Schizophrenia

NCTId NCT00044083
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 210 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
210 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2002-08
Primary completion
2015-12
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Tolcapone

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Jose A Apud, M.D.Principal Investigator

Sites

1 total
Bethesda, United States

Linked catalysts

1
Clinical Trial of Tolcapone for Cognition in Schizophrenia — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
210
Phase
PHASE2
Primary Completion Date
2015-12
Status
TERMINATED
relationships
The graph out of here
drug
Tolcapone
drug
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jose A Apud, M.D.
person